Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | HINT1 | P49773 | 4/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25966203 | 0.92 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL22335565 | 0.88 | KDM4E (0.45) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL24052001 | 0.85 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL25775085 | 0.85 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL25764957 | 0.85 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL25764906 | 0.85 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL26554435 | 0.85 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL7068744 | 0.84 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL19399420 | 0.84 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL7068737 | 0.84 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180524-B2 | Modified nucleoside phosphoramidites | Janssen Biopharma, Inc. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200255468-A1 | MODIFIED NUCLEOSIDE PHOSPHORAMIDITES | Janssen Pharmaceuticals, Inc. | 2020-08-13 | — | — | US | disclosed |
| WO-2019053659-A1 | MODIFIED NUCLEOSIDE PHOSPHORAMIDITES | ALIOS BIOPHARMA, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255468-A1 | MODIFIED NUCLEOSIDE PHOSPHORAMIDITES | PNP, MTAP, NT5C3B | KDM4E 2810/4885TAS1R3 3008/4885TAS1R1 2848/4885 |
| US-11180524-B2 | Modified nucleoside phosphoramidites | PNP, MTAP, NT5C3B | KDM4E 2810/4885TAS1R3 3008/4885TAS1R1 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.